(4-Bromo-2,6-difluorophenyl)trimethylsilane, 98%, 250mg

Crizotinib, 95%, 1g

Feuille de molybdène 99,95% 5 x 50 x 50 mm 1 pc

N1,N1'-(Butane-1,4-diyl)bis(propane-1,3-diamine) tetrahydrochloride, 95.0%, 25g

ethyl 6-isopropyl-4-oxo-1,4-dihydroquinoline-3-carboxylate, 97%, 250mg

Solution de nitrate d'argent, ROTI®Volum 0,1 mol/l - 0,1 N, ampoule, 1 pièce, emballage en verre

N-(4-Fluorophenyl)-3-oxo-butyramide, 10g

Diethyl vinylphosphonate, 97.0%, 1g

(6-Bromo-4-methylpyridin-3-yl)boronic acid, 97%, 1g

Methyl 3-Oxo-3-phenylpropanoate>98.0%(GC)(T)1g

trans-4-Aminocyclohexanecarboxylic Acid>98.0%(GC)(T)25g

(R)-N-(1-(7-(But-2-yn-1-yl)-3-methyl-1-((4-methylquinazolin-2-yl)methyl)-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-8-yl)piperidin-3-yl)-2,2,2-trifluoroacetamide (Linagliptin Impurity), 97%, 50mg

(1-Naphthylmethyl)triphenylphosphonium Chloride>98.0%(T)(HPLC)5g